

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Golden Meditech Holdings Limited

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 00801)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROFIT WARNING

This announcement is made by Golden Meditech Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) in relation to disclosure of inside information.

As disclosed in the profit warning announcement of the Company dated 12 June 2014, the Group is expected to record a loss for the year ended 31 March 2014 as compared to a profit recorded for the corresponding period in 2013 (the “**Corresponding Period**”), such loss being mainly attributable to (i) the increase in fair value loss as a result of the accounting treatment for certain convertible notes, as compared to the Corresponding Period; (ii) mark-to-market loss as a result of the decline in market values of certain securities investments, as opposed to a gain recorded in the Corresponding Period; and (iii) impairment losses on certain financial assets, intangible assets and interest in a joint venture. Based on information currently available in the audit process of the Group’s annual results for the year ended 31 March 2014, the board of directors of the Company (the “**Board**”) wishes to provide further information on the said items of loss as follows:

- (a) the fair value loss for certain convertible notes is expected to be approximately HK\$353 million as a result of the changes in fair value of the respective convertible notes issued by the Company and a subsidiary, namely China Cord Blood Corporation (“**CCBC**”), as compared to a loss of approximately HK\$21 million recorded in the Corresponding Period. Such changes were largely attributable to (i) the rise in the share price of CCBC to US\$4.0 per share as of 31 March 2014, which was approximately 40.9% above the conversion price of the convertible notes issued by CCBC, and increment of interest charges, thus resulting in a significant increase in its fair value; and (ii) the fair value loss incurred as a result of the early redemption by the Company of its convertible notes during the year ended 31 March 2014;

- (b) with respect to mark-to-market loss of certain securities investments, it is expected that the Group would record a net realised and unrealised loss on trading securities of approximately HK\$32 million, as compared to a net gain of approximately HK\$3 million recorded in the Corresponding Period;
- (c) with respect to impairment losses on certain financial assets, intangible assets and interest in a joint venture, during the year ended 31 March 2014, it is expected that the Group would record (i) non-cash impairment loss of approximately HK\$448 million and HK\$62 million respectively on the underlying intangible assets and trade receivables of the hospital management business, while no such losses were recorded in the Corresponding Period; (ii) non-cash impairment loss on available-for-sale equity securities of approximately HK\$25 million, while no such loss was recorded in the Corresponding Period; and (iii) share of losses of a joint venture of approximately HK\$61 million, as compared to a loss of less than HK\$1 million recorded in the Corresponding Period; and
- (d) based on the preliminary review of the unaudited consolidated management accounts of the Group, it is expected that the Group will record a loss of approximately HK\$713 million for the year ended 31 March 2014, as compared to a profit of approximately HK\$209 million recorded in the Corresponding Period.

The Company would like to reiterate that as it is still in the process of finalising the consolidated annual results of the Group for the year ended 31 March 2014, the information contained in this announcement only represents preliminary assessments and estimates by the Board based on the unaudited consolidated management accounts of the Group for the year ended 31 March 2014 and information currently available to it, and is not based on any financial figures or information which have been audited or reviewed by the Company's auditors. The finalised annual results of the Group for the year ended 31 March 2014 are expected to be announced on 24 June 2014. Shareholders and potential investors are advised to read the annual results announcement with care when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Golden Meditech Holdings Limited
Kam Yuen
Chairman

Hong Kong, 19 June 2014

As at the date of this announcement, the Board comprises 9 directors. The executive directors are Mr. KAM Yuen (Chairman), Mr. LU Tian Long, Mr. KONG Kam Yu and Mr. YU Kwok Kuen, Harry; the non-executive director is Ms. ZHENG Ting and the independent non-executive directors are Prof. CAO Gang, Mr. FENG Wen, Mr. GAO Zong Ze, and Prof. GU Qiao.